The Latest Analyst Ratings For Enovis
Portfolio Pulse from Benzinga Insights
Enovis (NYSE:ENOV) has been analyzed by four analysts, showing mixed sentiments. The average 12-month price target is $58.75, down from $65.67. Analysts have adjusted their ratings and price targets, reflecting changing market conditions. Enovis, a medical technology company, has shown significant revenue growth and strong financial metrics, despite a negative net margin.
October 03, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Enovis has received mixed analyst ratings, with a new average price target of $58.75, down from $65.67. Analysts have adjusted their ratings, reflecting changing market conditions. Despite a negative net margin, Enovis shows strong revenue growth and financial metrics.
The mixed analyst ratings and lowered price targets suggest a neutral short-term impact on Enovis's stock price. The company's strong revenue growth and financial metrics are positive, but the negative net margin and reduced price targets balance the outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100